SCHEMBL477053

SCHEMBL477053

Cc1cn2nc(Cl)cc(C)c2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
MAPT P10636 8/20 0.35
KDM4E B2RXH2 1/20 0.35
HTT P42858 2/20 0.33
SMPD3 Q9NY59 1/20 0.33
PDE10A Q9Y233 2/20 0.32
SMN1; SMN2 Q16637 7/20 0.32
RAB9A P51151 5/20 0.32
LMNA P02545 2/20 0.32
NPC1 O15118 4/20 0.32
L3MBTL1 Q9Y468 3/20 0.32
NFKB1 P19838 1/20 0.32
NFKB2 Q00653 1/20 0.32
RELA Q04206 1/20 0.32
MAPK1 P28482 1/20 0.32
KMT2A Q03164 3/20 0.31
MEN1 O00255 1/20 0.30
DYRK1A Q13627 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL25241165 0.98 ALDH1A1 (0.40) ALDH1A1HPGDHSD17B10MAPTKDM4E
Hydrochloric Acid SCHEMBL21979887 0.98 ALDH1A1 (0.40) ALDH1A1HPGDHSD17B10MAPTKDM4E
SCHEMBL30672025 0.90 ALDH1A1 (0.34) ALDH1A1HPGDHSD17B10MAPTKDM4E
SCHEMBL30672022 0.90 ALDH1A1 (0.37) ALDH1A1HPGDHSD17B10SMPD3PDE10A
SCHEMBL27008130 0.86 PDE10A (0.33) ALDH1A1MAPTKDM4EHTTPDE10A
SCHEMBL1826272 0.85 ALDH1A1 (0.41) ALDH1A1HPGDHSD17B10MAPTHTT
SCHEMBL30672019 0.82 ALDH1A1 (0.31) ALDH1A1HPGDHSD17B10
SCHEMBL30672020 0.82 ALDH1A1 (0.31) ALDH1A1HPGDHSD17B10
SCHEMBL3970342 0.82 KDM4E (0.52) ALDH1A1HPGDHSD17B10MAPTKDM4E
SCHEMBL1826708 0.81 ALDH1A1 (0.39) ALDH1A1HPGDHSD17B10MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120136877-A Synthesis method of 6-chloro-2, 8-dimethylimidazo [1,2-B ] pyridazine 扬州联澳生物医药有限公司 2025-06-13 CN claimed
EP-4724436-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING Remix Therapeutics Inc. (US) 2026-04-15 EP disclosed
US-20260098048-A1 IMPROVED PROCESS FOR THE PREPARATION OF RISDIPLAM AND ITS INTERMEDIATES NATCO PHARMA LTD (IN) 2026-04-09 US disclosed
US-12577226-B2 Compounds for treating Huntington's disease PTC THERAPEUTICS, INC. (US) 2026-03-17 US disclosed
US-20260008790-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY HOFFMANN-LA ROCHE INC. (US) 2026-01-08 US disclosed
EP-4663641-A2 PROCESS FOR THE PREPRATION OF 7-(4,7-DIAZASPIRO[2.5]OCTAN-7-YL)-2-(2,8-DIMETHYLIMIDAZO[1,2-B]PYRIDAZIN-6-YL)PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2025-12-17 EP disclosed
US-20250353841-A1 HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HUFF SARAH ELIZABETH (US) 2025-11-20 US disclosed
US-20250332173-A1 COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING REMIX THERAPEUTICS INC (US) 2025-10-30 US disclosed
EP-3684766-B1 PROCESS FOR THE PREPRATION OF 7-(4,7-DIAZASPIRO[2.5]OCTAN-7-YL)-2-(2,8-DIMETHYLIMIDAZO[1,2-B]PYRIDAZIN-6-YL)PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2025-10-29 EP disclosed
US-20250304582-A1 Bicyclic Ureas As Kinase Inhibitors INCYTE CORPORATION 2025-10-02 US disclosed
US-20100160163-A1 Fused heterocyclic sulfonylurea compound, herbicide containing the same, and method for controlling weed with the same TANAKA YASUSHI 2010-06-24 US disclosed
US-20100160163-A1 Fused heterocyclic sulfonylurea compound, herbicide containing the same, and method for controlling weed with the same TANAKA YASUSHI 2010-06-24 US disclosed
WO-2010018327-A1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2010-02-18 WO disclosed
WO-2010018327-A1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2010-02-18 WO disclosed
US-20090247748-A1 PROCESS FOR PRODUCING SULFONYL CHLORIDE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-10-01 US disclosed
EP-1466527-B1 FUSED HETEROCYCLIC SULFONYLUREA COMPOUND, HERBICIDE CONTAINING THE SAME, AND METHOD OF CONTROLLING WEED WITH THE SAME SUMITOMO CHEMICAL CO (JP) 2008-07-16 EP disclosed
EP-1466527-B1 FUSED HETEROCYCLIC SULFONYLUREA COMPOUND, HERBICIDE CONTAINING THE SAME, AND METHOD OF CONTROLLING WEED WITH THE SAME SUMITOMO CHEMICAL CO (JP) 2008-07-16 EP disclosed
EP-1932846-A1 METHOD FOR PRODUCING SULFONYL CHLORIDE COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-06-18 EP disclosed
US-20050032650-A1 Fused heterocyclic sulfonylurea compound herbicide containing the same and method of controlling weed with the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-02-10 US disclosed
EP-1466527-A1 FUSED HETEROCYCLIC SULFONYLUREA COMPOUND, HERBICIDE CONTAINING THE SAME, AND METHOD OF CONTROLLING WEED WITH THE SAME Sumitomo Chemical Takeda Agro Company, Limited (JP) 2004-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260008790-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, RBM22, RBM17 ALDH1A1 2678/4885HPGD 4560/4885HSD17B10 3797/4885
US-20090247748-A1 PROCESS FOR PRODUCING SULFONYL CHLORIDE COMPOUND SALL4, CLCN2, CLIC1 ALDH1A1 1418/4885HPGD 4787/4885HSD17B10 2253/4885
US-20250332173-A1 COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING SNRPA, NSUN2, SNRPA1 ALDH1A1 3447/4885HPGD 4053/4885HSD17B10 2875/4885
US-20260098048-A1 IMPROVED PROCESS FOR THE PREPARATION OF RISDIPLAM AND ITS INTERMEDIATES AOC1, ODC1, OTC ALDH1A1 1092/4885HPGD 3101/4885HSD17B10 4721/4885
US-20250353841-A1 HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, ATXN2 ALDH1A1 2917/4885HPGD 764/4885HSD17B10 224/4885
US-20100160163-A1 Fused heterocyclic sulfonylurea compound, herbicide containing the same, and method for controlling weed with the same NOTUM, WEE1, DDT ALDH1A1 670/4885HPGD 3244/4885HSD17B10 1038/4885
US-20250304582-A1 Bicyclic Ureas As Kinase Inhibitors JAK2, UCK2, ULK2 ALDH1A1 3820/4885HPGD 1830/4885HSD17B10 3742/4885
US-12577226-B2 Compounds for treating Huntington's disease HTT, HYPK, GRIN2C ALDH1A1 2086/4885HPGD 988/4885HSD17B10 193/4885
US-20050032650-A1 Fused heterocyclic sulfonylurea compound herbicide containing the same and method of controlling weed with the same NOTUM, WEE1, DDT ALDH1A1 671/4885HPGD 3258/4885HSD17B10 1095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.